Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Arakoda (Tafenoquine) in Babesiosis. The expected timing is based on the latest available company guidance and may change.
05/15/26:- PR No update. 05/26/26:- NCT06207370 enrolled first patient; minimum interim-analysis enrollment expected Early July 2026. Interim analyses date to follow. 07/29/26:- NCT06207370 minimum 24 patients enrolled; interim analysis results due by October 6, 2026. FDA meeting planned after interim. 08/14/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.